"In our view, the ability to generate high quality wet-lab data is critical for advancement," analyst says in initiating ...

We recently compiled a list of the Top 10 Medical AI Stocks on Wall Street’s Radar. In this article, we are going to take a ...

Needham analyst has initiated coverage on Absci Corporation (NASDAQ:ABSI), a drug and target discovery company that harnesses ...

Needham analyst Gil Blum initiated coverage of Absci (ABSI) with a Buy rating and $9 price target Absci “stands out from the pack due to its ...

Absci Corp (ABSI) stock saw a decline, ending the day at $4 which represents a decrease of $-0.17 or -4.08% from the prior close of $4.17. The stock opened at $4.16 and touched a low of $3.92 during ...

Truist Financial analyst Srikripa Devarakonda assigned a Buy rating to the stock today. The company’s shares closed last Friday at $2.90.Invest ...

Fintel reports that on January 22, 2025, Needham initiated coverage of Absci (NasdaqGS:ABSI) with a Buy recommendation.

Insights from analysts' 12-month price targets are revealed, presenting an average target of $7.14, a high estimate of $10.00, and a low estimate of $5.00. This current average represents a 2.06% ...

Equities research analysts at Needham & Company LLC assumed coverage on shares of Absci (NASDAQ:ABSI – Get Free Report) in a ...

Absci recently received a $20 million PIPE investment from AMD that improves its runway and R&D platform with AI. See why I ...

Needham initiates Absci coverage with a Buy rating and a $9 price target, citing robust proprietary technology. Absci’s partnerships with Merck, AstraZeneca, and Almirall provide milestone ...